You will join the group of prof. dr. Timo K. van den Berg that is focusing on the role of innate immune cells in immunotherapy of cancer and other diseases.  

Our laboratory was among the pioneering ones discovering that the interaction between CD47 expressed on cancer cells and the inhibitory receptor SIRPa on phagocytes functions as an immune checkpoint that upon disruption can promote antibody-mediated destruction of cancer cells (Zhao XW et al. (2011) PNAS 108:18342–18347). 

With encouraging results from the first clinical trials using therapeutic agents targeting CD47-SIRP in recent years this has now become one of the most exciting and rapidly expanding fields in cancer immunotherapy. 
You will work in a dynamic environment where both fundamental and translational research related to immunotherapy is being performed.

• motivated and talented candidate with an MSc in Biomedical Sciences or a related degree and an interest in immunology and oncology
• experience with cellular and molecular techniques.
• excellent communication skills, also in English.

Fixed-term contract: 4 years.

• challenging and clinically relevant project; 
• position for 4 years; 
• 8,33% end-of-year bonus; 
• 8,33% holiday allowance; 
• 201 hours of leave with fulltime employment (36 hours);
• partial reimbursement of travel expenses;
• pension plan with Pensioenfonds Zorg & Welzijn (PFZW);
• collective agreement with various insurance companies;
• a multiple-choice system that enables employees to select their own preferred terms of employment;
• fulltime employment (36 hours) with 201 hours of leave per annum.

Sanquin

Sanquin is one of the few organizations in the world to combine medical, diagnostic and scientific activities under the same roof, all in the field of blood. With 2,000 committed colleagues and 345,000 blood donors, we can provide a better life for 300,000 patients each year.